Vertex Pharmaceuticals Inc

2026-07-02 20:03; UTC

Vertex Pharmaceuticals shares are higher following FDA approval for expanded use of CASGEVY, now available for children as young as 2 years old.

2026-07-01 20:06; UTC

Vertex Pharmaceuticals shares are advancing, reflecting broader market trends. The stock remains above its 20-day moving average despite an earlier session pullback.

2026-06-30 20:07; UTC

Vertex Pharmaceuticals is trading lower amid broader market pressures despite promising first-quarter results. Earlier in the session, shares briefly reached a high before declining.

2026-06-29 19:31; UTC

Vertex Pharmaceuticals is trading higher, driven by positive analyst sentiment and revised earnings estimates ahead of its upcoming earnings report.

2026-06-26 20:04; UTC

Vertex Pharmaceuticals is rising as biotechnology stocks advance during Friday's session. The stock remains above its 20-day moving average after five consecutive higher closes.

2026-06-25 20:02; UTC

Vertex Pharmaceuticals is trading higher today amid notable volatility, reflecting a broader trend since Wednesday's close, despite no specific company news.

2026-06-24 23:26; UTC

Vertex Pharmaceuticals is lower in after-market hours, driven by declines in the Biotechnology sub-sector. The stock remains above its 20-day moving average.

2026-06-23 19:36; UTC

Vertex Pharmaceuticals shares are higher today, recovering from an earlier pullback. The stock remains near the upper end of its one-month trading range.

2026-06-22 20:02; UTC

Vertex Pharmaceuticals is higher today, supported by a diverse pipeline in kidney disease and favorable market conditions following easing U.S.-Iran tensions.

2026-06-18 19:52; UTC

Vertex Pharmaceuticals shares are lower today as biotechnology stocks face pressure. Earlier in the session, shares peaked before reversing direction.

2026-06-17 19:54; UTC

Vertex Pharmaceuticals is rising amid a positive Biotechnology sector trend and favorable Federal Reserve interest rate decisions, boosting investor confidence in healthcare.

2026-06-16 23:16; UTC

Vertex Pharmaceuticals Inc shares are lower in after-market hours. Market sentiment is influenced by optimism over a potential U.S.-Iran peace deal.

2026-06-15 12:46; UTC

Vertex Pharmaceuticals is roughly flat in pre-market hours, maintaining a routine performance and remaining above its 20-day moving average.

2026-06-12 19:36; UTC

Vertex Pharmaceuticals shares are higher today, reflecting stable trading conditions. The stock is positioned above its 20-day moving average, indicating positive market sentiment.

2026-06-11 23:56; UTC

Vertex Pharmaceuticals announced clinical benefits of CASGEVY® for severe sickle cell disease. Shares are trading lower in after-market hours, within a typical trading range.

2026-06-10 20:03; UTC

Vertex Pharmaceuticals shares are lower as inflation data aligns with forecasts. The stock continues to trade below its 20-day moving average.

2026-06-09 19:56; UTC

Vertex Pharmaceuticals shares are higher during Tuesday's session, having peaked earlier, though they have pulled back slightly. No specific news was identified for this movement.

2026-06-08 19:36; UTC

Vertex Pharmaceuticals shares are lower despite positive data on ALYFTREK for cystic fibrosis. The decline follows broader market dynamics after a strong U.S. jobs report.

2026-06-05 23:06; UTC

Vertex Pharmaceuticals shares are trading lower in after-market hours, with no specific news identified. Broader market conditions may be influencing the stock's movement.

2026-06-04 20:02; UTC

RBC reiterated its Outperform rating on Vertex Pharmaceuticals with a $543 price target, contributing to shares advancing despite an earlier pullback.

2026-06-03 23:06; UTC

Vertex Pharmaceuticals shares are trading higher in after-market hours. No specific news was identified to explain this movement amid broader market volatility.

2026-06-02 20:03; UTC

Vertex Pharmaceuticals' FDA acceptance of povetacicept application fails to lift shares, which are trading lower and below their 20-day moving average.

2026-06-01 19:41; UTC

Vertex Pharmaceuticals' Biologics License Application for povetacicept accepted by the FDA. Shares are lower today amid broader market sentiment despite this milestone.

2026-05-29 22:06; UTC

Vertex Pharmaceuticals shares are higher in after-market hours, trading near the upper end of their one-month range and above their 20-day moving average.

2026-05-28 20:02; UTC

Vertex Pharmaceuticals shares are higher today, continuing a steady upward trend since Wednesday. Broader market reactions to geopolitical tensions are influencing trading.

2026-05-27 19:46; UTC

Truist Securities initiated coverage of Vertex Pharmaceuticals with a Buy rating and raised the price target to $542, contributing to today's price gain.

2026-05-26 19:56; UTC

Vertex Pharmaceuticals shares are higher today, continuing recent upward momentum. No specific company news was identified to explain the price movement.

2026-05-22 19:26; UTC

Vertex Pharmaceuticals shares are higher as Health Canada reviews suzetrigine, a new oral pain treatment. The stock shows modest gains since Thursday's close.

2026-05-21 19:56; UTC

Vertex Pharmaceuticals shares rise as Health Canada reviews suzetrigine for acute pain treatment, marking a potential breakthrough in oral pain medication.